Subscribe
shutterstock_1952511289_postmodern_studio
Postmodern Studio / Shutterstock.com
25 January 2024Big PharmaLiz Hockley

Nivagen accuses India-based big pharma of ‘meddling’ in patent application

Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.
Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More on this story

Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.
Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers